Risedronic acid, often used as its sodium salt risedronate sodium, is a bisphosphonate.[1] It slows down the cells which break down bone.[1] It's used to treat or prevent osteoporosis, and treat Paget's disease of bone.[1] It is taken by mouth.[1]
It was patented in 1984 and approved for medical use in 1998.[2]
Pharmacology
History
Risedronate, known as NE-58095 while under development, was discovered by scientists at the Cincinnati Miami Valley Laboratories and the Norwich Eaton Laboratories of Procter and Gamble. [4]
Society and culture
Brand names
It is produced and marketed by Warner Chilcott, Sanofi-Aventis, and in Japan by Takeda under the trade names Actonel, Atelvia, and Benet. It is also available in a preparation that includes a calcium carbonate supplement, as Actonel with Calcium.
Controversies
In January 2006 P&G and its marketing partner Sanofi-Aventis filed a Lanham Act false claims lawsuit against rival drugmakers Roche and GlaxoSmithKline claiming false advertising about Boniva.[5] The manufacturers of Boniva, a rival bisphosphonate, were accused in the suit of causing a "serious public health risk" through misrepresentation of scientific findings. In a ruling on September 7, 2006, U.S. District Judge
External links
References
- Actonel- risedronate sodium tablet, film coated DailyMed, 1 November 2019, retrieved 28 June 2022^
- Analogue-based Drug Discovery John Wiley & Sons, 2006^
- Essentials of medical pharmacology Jaypee Brothers Medical Publishers Ltd., 30 September 2013^